帕唑帕尼谷浓度个体内变异与肾细胞癌及软组织肉瘤患者临床结局的关联探索
本研究纳入144例接受帕唑帕尼治疗并常规进行治疗药物监测的转移性肾细胞癌或软组织肉瘤患者,基于至少三次谷浓度计算个体内变异。结果显示,肾细胞癌患者中高个体内变异(>30.2%)与更差的无进展生存和总生存相关,而软组织肉瘤患者中未建立此关联。
要点
- 肾细胞癌患者中,帕唑帕尼谷浓度个体内变异>30.2%与更差的无进展生存和总生存相关。
- 软组织肉瘤患者中未发现高个体内变异与临床结局的关联。
- 高个体内变异提示临床医生应关注治疗依从性、药物相互作用及食物-药物相互作用。
核心结论
- 高个体内变异与帕唑帕尼治疗患者更差的临床结局相关,尤其在肾细胞癌患者中。
研究设计与样本
- 回顾性研究,纳入144例接受帕唑帕尼治疗且至少有三项谷浓度监测数据的转移性肾细胞癌或软组织肉瘤患者。
主要发现
- 144例患者中,帕唑帕尼个体内变异的中位数为30.2%。
- 肾细胞癌患者中,高个体内变异组(>30.2%)的无进展生存风险比为1.42(95% CI 0.85-2.35)。
- 肾细胞癌患者中,高个体内变异组的总生存风险比为2.17(95% CI 1.10-4.29)。
- 软组织肉瘤患者中未发现高个体内变异与临床结局的关联。
关键数值与推荐
- 帕唑帕尼药代动力学的个体内变异平均值为24.7%。
- 高个体内变异定义为个体内变异>30.2%。
临床怎么用
- 高个体内变异提示临床医生应关注治疗依从性、药物相互作用及食物-药物相互作用,以改善治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well-established exposure-response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy-toxicity balance. Intra-patient variability in pazopanib pharmacokinetics is moderate with a mean of 24.7%. In other fields, such as transplantation medicine, a high intra-patient variability of immunosuppressive drugs has previously been associated with worse outcomes. Whether this also applies to therapeutic modalities in oncology is unknown. The aim of this study was to explore the relationship between pazopanib intra-patient variability and clinical outcomes. Data from patients diagnosed with either metastatic renal cell carcinoma or soft tissue sarcoma treated with pazopanib guided by routine therapeutic drug monitoring with at least three available pazopanib trough concentrations were retrieved. Non-dose corrected estimated trough concentrations were used to calculate intra-patient variability. Among 144 patients, median intra-patient variability was 30.2%. The high intra-patient variability group (intra-patient variability > 30.2%) was at risk for worse progression-free survival (HR 1.42; 95% CI 0.85-2.35) and overall survival (HR 2.17; 95% CI 1.10-4.29) in patients with renal cell carcinoma. No association between a high intra-patient variability and clinical outcomes for patients with soft tissue sarcoma could be established. Our results show that high intra-patient variability is associated with poorer treatment outcomes. A high intra-patient variability urges the treating clinician to address therapy adherence, drug-drug and food-drug interactions, and improve chances for optimal treatment outcome.
引用
- Rieborn A, Giraud EL, van Gelder T, et al. Exploring the Association Between Intra-Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients. Clin Pharmacol Ther. 2025. PMID: 40450699. doi:10.1002/cpt.3728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。